Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;20(37):2983-2992.
doi: 10.1080/14796694.2024.2407282. Epub 2024 Oct 4.

The epidemiology, treatments and outcomes of patients with hormone receptor positive, human epidermal growth factor receptor 2 negative, node-positive early breast cancer in Taiwan

Chao-Hsiun Tang  1 , Rachel Sarah Newson  2 , Ching-Hung Lin  3 , Bill Hoi-Fong Chan  4 , Bruce Cm Wang  5 , Shih-Pei Shen  1 , Serena Yu-Ju Shao  4
Affiliations

The epidemiology, treatments and outcomes of patients with hormone receptor positive, human epidermal growth factor receptor 2 negative, node-positive early breast cancer in Taiwan

Chao-Hsiun Tang et al. Future Oncol. 2024.

Abstract

Aim: Estimate patient counts, treatment patterns and outcomes of a subset of patients with early breast cancer (EBC) presenting with hormone receptor positive, human epidermal growth factor receptor 2 negative, node positive features, who are at high-risk of recurrence, in Taiwan.Materials & methods: Data from Taiwan's National Health Insurance Research Database and Taiwan Cancer Registry from 1 January 2011 to 31 December 2020 were analyzed.Results: There were 4500 patients with high-risk EBC (10.4% of all patients with EBC) from 2012 to 2018, with an annual average incidence of 643 that increased over time. Five-year progression was 24.8% in patients with high-risk EBC and 8-year survival was low (69.6%).Conclusion: Patients with hormone receptor positive, human epidermal growth factor receptor 2 negative, node positive high-risk EBC clinical features are an increasing high-risk subset of all patients with EBC.

Keywords: HER2-; HR+; early breast cancer; health economics; high-risk; node-positive.

Plain language summary

[Box: see text].

PubMed Disclaimer

Conflict of interest statement

SYJ Shao, RS Newson and BHF Chan are employees of Eli Lilly and Co. and BCM Wang is a paid consultant to Eli Lilly and Co. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Figures

Figure 1.
Figure 1.
Kaplan–Meier—Time to all-cause mortality, high-risk early breast cancer subgroups.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers. 2021;13(17):4287. doi:10.3390/cancers13174287 - DOI - PMC - PubMed
    1. Ben-Dror J, Shalamov M, Sonnenblick A. The history of early breast cancer treatment. Genes. 2022;13(6):960. doi:10.3390/genes13060960 - DOI - PMC - PubMed
    1. Lin K-H, Hsu H-M, Hsu K-F, et al. . Survival outcomes in elderly Taiwanese women according to breast cancer subtype and lymph node status: a single-center retrospective study. PloS One. 2021;16(12):e0261258–e0261258. doi:10.1371/journal.pone.0261258 - DOI - PMC - PubMed
    1. Chen Y-C, Su S-Y, Jhuang J-R, et al. . Forecast of a future leveling of the incidence trends of female breast cancer in Taiwan: an age-period-cohort analysis. Sci Rep. 2022;12(1):12481–12481. doi:10.1038/s41598-022-16056-y - DOI - PMC - PubMed
    1. Huang S-Y, Chen H-M, Liao K-H, Ko B-S, Hsiao F-Y. Economic burden of cancers in Taiwan: a direct and indirect cost estimate for 2007-2017. BMJ Open. 2020;10(10):e036341–e036341. doi:10.1136/bmjopen-2019-036341 - DOI - PMC - PubMed

MeSH terms

Grants and funding